{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:41:19Z","timestamp":1780486879819,"version":"3.54.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.4158\/ep08306.orr1","type":"journal-article","created":{"date-parts":[[2009,6,2]],"date-time":"2009-06-02T21:14:03Z","timestamp":1243977243000},"page":"483-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates"],"prefix":"10.1016","volume":"15","author":[{"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 suppl 1","key":"10.4158\/EP08306.ORR1_bb0005","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bone.2005.11.024","article-title":"Osteoporosis: a still increasing prevalence","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone."},{"key":"10.4158\/EP08306.ORR1_bb0010","unstructured":"National Osteoporosis Foundation. Fast Facts on Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008. http:\/\/www.nof.org\/osteoporosis\/diseasefacts.htm. Accessed for verification April 27, 2009."},{"key":"10.4158\/EP08306.ORR1_bb0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08306.ORR1_bb0020","series-title":"Invest in Your Bones. Quality of Life: Why Prevent the First Fracture?","author":"International Osteoporosis Foundation","year":"2009"},{"key":"10.4158\/EP08306.ORR1_bb0025","series-title":"Facts and Statistics About Osteoporosis and Its Impact","author":"International Osteoporosis Foundation","year":"2009"},{"key":"10.4158\/EP08306.ORR1_bb0030","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s001980200033","article-title":"Direct medical costs attributable to osteoporotic fractures","volume":"13","author":"Gabriel","year":"2002","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0035","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00198-004-1622-5","article-title":"Health-related quality of life after osteoporotic fractures","volume":"15","author":"Hallberg","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0040","series-title":"Advocacy News and Updates. America\u2019s Bone Health: The State of Osteoporosis and Low Bone Mass","author":"National Osteoporosis Foundation","year":"2009"},{"key":"10.4158\/EP08306.ORR1_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ncpendmet0121","article-title":"Drug insight: bisphosphonates for postmenopausal osteoporosis","volume":"2","author":"Chapurlat","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab."},{"key":"10.4158\/EP08306.ORR1_bb0050","series-title":"Fosamax [package insert]. Whitehouse Station","year":"2007"},{"key":"10.4158\/EP08306.ORR1_bb0055","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","article-title":"Compliance with osteoporosis medications","volume":"165","author":"Solomon","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP08306.ORR1_bb0060","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1359\/JBMR.041214","article-title":"(IMPACT Study Group). Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study","volume":"20","author":"Delmas","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08306.ORR1_bb0065","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/archinte.163.17.2052","article-title":"Low frequency of treatment of osteoporosis among postmenopausal women following a fracture","volume":"163","author":"Andrade","year":"2003","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP08306.ORR1_bb0070","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification and fracture outcomes of undiagnosed low bone density in postmenopausal women: results from the National Osteoporosis Risk Assessment","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/EP08306.ORR1_bb0075","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP08306.ORR1_bb0080","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The population burden of fractures originates in women with osteopenia, not osteoporosis","volume":"17","author":"Pasco","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0085","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1503\/cmaj.070234","article-title":"Low bone mineral density and fracture burden in postmenopausal women","volume":"177","author":"Cranney","year":"2007","journal-title":"CMAJ."},{"key":"10.4158\/EP08306.ORR1_bb0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","article-title":"(European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis [ESCEO]). European guidance for the diagnosis and management of osteoporosis in postmenopausal women [published correction appears in Osteoporos Int. 2008;19:1103-1104]","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0095","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00198-006-0310-z","article-title":"Fracture risk and antiresorptive medication use in older women in the USA","volume":"18","author":"Gehlbach","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0100","series-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","author":"National Osteoporosis Foundation","year":"2009"},{"issue":"suppl 4","key":"10.4158\/EP08306.ORR1_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist."},{"key":"10.4158\/EP08306.ORR1_bb0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structureactivity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharm Exp Ther."},{"key":"10.4158\/EP08306.ORR1_bb0115","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.4158\/EP08306.ORR1_bb0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP08306.ORR1_bb0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"(Vertebral Efficacy With Risedronate Therapy [VERT] Study Group). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"(Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe [BONE]). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08306.ORR1_bb0135","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study [published correction appears in Ann Rheum Dis. 2008;67:280]","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.4158\/EP08306.ORR1_bb0140","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing IntraVenous Administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.4158\/EP08306.ORR1_bb0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","article-title":"Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies","volume":"24","author":"Harris","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP08306.ORR1_bb0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","article-title":"Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data","volume":"20","author":"Cranney","year":"2009","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","article-title":"Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis","volume":"44","author":"Sebba","year":"2009","journal-title":"Bone."},{"key":"10.4158\/EP08306.ORR1_bb0160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00198-006-0294-8","article-title":"Non-compliance: the Achilles\u2019 heel of anti-fracture efficacy","volume":"18","author":"Seeman","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0165","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"10.4158\/EP08306.ORR1_bb0170","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0175","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bone.2007.07.009","article-title":"Consequences of poor compliance with bisphosphonates","volume":"41","author":"Briesacher","year":"2007","journal-title":"Bone."},{"key":"10.4158\/EP08306.ORR1_bb0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-006-0230-y","article-title":"Compliance with osteoporosis drug therapy and risk of fracture","volume":"18","author":"Weycker","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0185","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","article-title":"Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women","volume":"19","author":"Rabenda","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0190","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1185\/030079907X226339","article-title":"Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates","volume":"23","author":"Earnshaw","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP08306.ORR1_bb0195","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP08306.ORR1_bb0205","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005","journal-title":"Mayo Clin Proc."},{"key":"10.4158\/EP08306.ORR1_bb0210","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","article-title":"Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis","volume":"28","author":"Penning-van Beest","year":"2006","journal-title":"Clin Ther."},{"key":"10.4158\/EP08306.ORR1_bb0215","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","article-title":"Brankin E (PERSIST Investigators). Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study","volume":"60","author":"Cooper","year":"2006","journal-title":"Int J Clin Pract."},{"key":"10.4158\/EP08306.ORR1_bb0220","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1185\/030079907X226069","article-title":"Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills","volume":"23","author":"Weiss","year":"2007","journal-title":"Curr Res Med Opin."},{"key":"10.4158\/EP08306.ORR1_bb0225","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol."},{"key":"10.4158\/EP08306.ORR1_bb0230","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"(HORIZON Pivotal Fracture Trial). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP08306.ORR1_bb0235","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"(HORIZON Recurrent Fracture Trial). Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP08306.ORR1_bb0240","unstructured":"Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of first dose of zoledronic acid after hip fracture [published online ahead of print March 3, 2009]. J Bone Miner Res. doi:https:\/\/doi.org\/10.1359\/jbmr090209."},{"key":"10.4158\/EP08306.ORR1_bb0245","series-title":"Reclast [package insert]. East Hanover","year":"2009"},{"key":"10.4158\/EP08306.ORR1_bb0250","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, doubledummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.4158\/EP08306.ORR1_bb0255","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone."},{"key":"10.4158\/EP08306.ORR1_bb0260","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"(American Society for Bone and Mineral Research). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08306.ORR1_bb0265","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145:235]","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP08306.ORR1_bb0270","first-page":"A-3078","article-title":"Onkologie: Kiefernekrosen nach hoch dosierter bisphosphonattherapie [article in Dutch]","volume":"103","author":"Felsenberg","year":"2006","journal-title":"Deutsches Arztebattl"},{"key":"10.4158\/EP08306.ORR1_bb0275","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","article-title":"Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations","volume":"137","author":"American Dental Association Council on Scientific Affairs","year":"2006","journal-title":"J Am Dental Assoc."},{"key":"10.4158\/EP08306.ORR1_bb0280","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14219\/jada.archive.2008.0017","volume":"139","author":"Grbic","year":"2008","journal-title":"J Am Dent Assoc."},{"key":"10.4158\/EP08306.ORR1_bb0285","series-title":"Zometa [package insert]. East Hanover","year":"2007"},{"key":"10.4158\/EP08306.ORR1_bb0290","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/EP08306.ORR1_bb0295","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation [letter]","volume":"356","author":"Cummings","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP08306.ORR1_bb0300","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/EP08306.ORR1_bb0305","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP08306.ORR1_bb0310","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"(PaTH Study Investigators). The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP08306.ORR1_bb0315","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev."},{"issue":"suppl 1","key":"10.4158\/EP08306.ORR1_bb0320","first-page":"S113","article-title":"Chronic subcutaneous, but not single intravenous dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH [abstract F386]","volume":"21","author":"Gasser","year":"2006","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08306.ORR1_bb0325","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med."},{"issue":"suppl 1","key":"10.4158\/EP08306.ORR1_bb0330","first-page":"S48","article-title":"Histomorphometric and biochemical bone formation responses to first and second cycles of teriparatide treatment [abstract 1169]","volume":"23","author":"Lindsay","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"suppl 1","key":"10.4158\/EP08306.ORR1_bb0335","first-page":"S89","article-title":"Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate [abstract O423]","volume":"22","author":"Cosman","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08306.ORR1_bb0340","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh","year":"2007","journal-title":"J Bone Joint Surg Br."},{"key":"10.4158\/EP08306.ORR1_bb0345","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08306.ORR1_bb0350","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/EP08306.ORR1_bb0355","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?","volume":"39","author":"Kwek","year":"2008","journal-title":"Injury."},{"key":"10.4158\/EP08306.ORR1_bb0360","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"Neviaser","year":"2008","journal-title":"J Orthop Trauma."},{"key":"10.4158\/EP08306.ORR1_bb0365","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility","volume":"93","author":"Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08306.ORR1_bb0370","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX); a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.4158\/EP08306.ORR1_bb0375","first-page":"S16","article-title":"Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: the FLEX trial [abstract 1057]","volume":"22","author":"Schwartz","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08306.ORR1_bb0380","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20411693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20411693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/2455R410706XQH7V.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:49:45Z","timestamp":1761515385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20411693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S1530891X20411693"],"URL":"https:\/\/doi.org\/10.4158\/ep08306.orr1","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP08306.ORR1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}